peoplePerson
Aurélien Marabelle
Aurélien Marabelle is the immunotherapy investigator behind the tumour-agnostic pembrolizumab data in MSI-high cancers.
Aurélien Marabelle leads early-phase immunotherapy at Gustave Roussy's DITEP. He was lead author of the KEYNOTE-158 analysis that supported pembrolizumab's tumour-agnostic approvals and works on intratumoural immunotherapy.
Role
Clinical Director, Cancer Immunotherapy Program (DITEP), Gustave Roussy
Institution
Specialisms
Immuno-oncologyEarly-phase immunotherapyMSI-high tumoursIntratumoural therapy
Profiles